Suzuki, Y.
Kaneko, H.
Okada, A.
Ohno, R.
Yokota, I.
Fujiu, K.
Jo, T.
Takeda, N.
Morita, H.
Node, K.
Yasunaga, H.
Komuro, I.
Funding for this research was provided by:
Ministry of Health, Labour and Welfare (21AA2007)
the Ministry of Education, Culture, Sports, Science and Technology (20H03907, 21H03159, 21K08123, 22K21133)
The University of Tokyo
Article History
Received: 25 August 2023
Accepted: 11 November 2023
First Online: 19 December 2023
Declarations
:
: Research funding and scholarship funds (Hidehiro Kaneko and Katsuhito Fujiu) from Medtronic Japan CO., LTD, Boston Scientific Japan CO., LTD, Biotronik Japan, Simplex QUANTUM CO., LTD, and Fukuda Denshi, Central Tokyo CO., LTD. Issei Komuro received remuneration for lecture from AstraZeneca K.K, MSD K.K, Otsuka Pharmaceutical Co. Ltd., ONO PHARMACEUTICAL CO. LTD., DAIICHI SANKYO COMPANY LIMITED., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co. Ltd., BAYER YAKUHIN, LTD., Novo Nordisk Pharma Ltd., Pfizer Japan Inc and trust research/joint research funds from ONO PHARMACEUTICAL CO. LTD. and scholarship fund from Idorsia Pharmaceuticals Japan Ltd., MSD K.K., ONO PHARMACEUTICAL CO. LTD., Sanofi K. K., DAIICHI SANKYO COMPANY LIMITED., Dainippon Sumitomo Pharma Co. Ltd., Takeda Pharmaceutical Company Limited., Mitsubishi Tanabe Pharma Corporation, TEIJIN PHARMA LIMITED, TOA EIYO LTD. Isao Yokota reports research fund by Nihon Medi-Physics, and speaker fees from Chugai Pharmaceutical Co, and AstraZeneca, outside the submitted work.
: This study was approved by the Ethics Committee of the University of Tokyo (approval number: 2018-10862). We conducted this study conforming to the principles outlined in the Declaration of Helsinki.
: Informed consent was not required because all data included in the JMDC Claims Database were anonymized and de-identified.
: Name of the ethics committee: the Clinical Research Review Board of The University of Tokyo [2018-10862].